Hogan Lovells Advises the Shareholders Of Internis Pharmaceuticals on its Sale to Stada Arzneimittel
Hogan Lovells has advised the shareholders of UK-based Internis Pharmaceuticals on its sale to German pharmaceutical company Stada Arzneimittel for £49 million.
The sale included Internis Pharmaceuticals’ Fultium-D3 prescription medicine for treating vitamin D3 deficiency.